CYDX (Cyduct Diagnostics) LT-Debt-to-Total-Asset: 0.00 (As of . 20)


What is Cyduct Diagnostics LT-Debt-to-Total-Asset?

Cyduct Diagnostics CYDX -17.78% LT-Debt-to-Total-Asset is 0.00 as of . 20.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Cyduct Diagnostics's long-term debt to total assests ratio for the quarter that ended in . 20 was 0.00.

Cyduct Diagnostics's long-term debt to total assets ratio stayed the same from . 20 (0.00) to . 20 (0.00).

Cyduct Diagnostics  (OTCPK:CYDX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Cyduct Diagnostics LT-Debt-to-Total-Asset Related Terms

Cyduct Diagnostics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Cyduct Diagnostics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyduct Diagnostics LT-Debt-to-Total-Asset Chart

Cyduct Diagnostics Annual Data
Trend
LT-Debt-to-Total-Asset

Cyduct Diagnostics Quarterly Data
LT-Debt-to-Total-Asset

Cyduct Diagnostics LT-Debt-to-Total-Asset Calculation

Cyduct Diagnostics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in . 20 is calculated as

LT Debt to Total Assets (A: . 20 )=Long-Term Debt & Capital Lease Obligation (A: . 20 )/Total Assets (A: . 20 )
=/
=

Cyduct Diagnostics's Long-Term Debt to Total Asset Ratio for the quarter that ended in . 20 is calculated as

LT Debt to Total Assets (Q: . 20 )=Long-Term Debt & Capital Lease Obligation (Q: . 20 )/Total Assets (Q: . 20 )
=/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Cyduct Diagnostics (CYDX) has a LT-Debt-to-Total-Asset of 0.00 as of . 20. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Cyduct Diagnostics and its competitors.
Is Cyduct Diagnostics' LT-Debt-to-Total-Asset too high?
Cyduct Diagnostics' current LT-Debt-to-Total-Asset is 0.00.
How does Cyduct Diagnostics' LT-Debt-to-Total-Asset compare to SECI and QTXB?
Cyduct Diagnostics' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?
A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Cyduct Diagnostics and its competitors. Cyduct Diagnostics's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyduct Diagnostics stock overvalued right now?
Cyduct Diagnostics (CYDX) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Cyduct Diagnostics (CYDX), the current LT-Debt-to-Total-Asset is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cyduct Diagnostics Business Description

Address 1698 Post Road East, Suite 1A, Westport, CT, USA, 06880
Cyduct Diagnostics Inc is a clinical-stage diagnostic company. It focuses on creating and enhancing a portfolio of technologies and assets based on the early assessment and detection of Breast Cancer. Its technology platform of MammoView devices is a single-use, high-margin product that assesses, screens, detects, monitors, and facilitates the treatment of identifiable changes that distinguish variations in breast health. The company markets these products under its Solos Endoscopy brand, along with a line of branded surgical instruments, manufactured by third parties to its design specifications, mainly endoscopes and hand-held surgical instruments for the minimally invasive surgery market.